Growth Hormone Replacement Changes Brain Chemistry — First Direct Evidence

One month of GH replacement in deficient adults changed CSF levels of GH, IGF-1, monoamine metabolites, neuropeptides, and opioid peptides.

Johansson, J O et al.·Neuroendocrinology·1995·Strong EvidenceRCT
RPEP-00324RCTStrong Evidence1995RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
RCT
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

One month of GH replacement increased CSF GH and IGF-1 while altering monoamine metabolites, neuropeptides, and opioid peptide concentrations.

Key Numbers

How They Did This

Double-blind, placebo-controlled trial in 20 adults with GH deficiency (10 per group). CSF collected before and after 1 month of treatment (0.25 U/kg/week). Measured GH, IGF-1, IGFBP-3, monoamine metabolites, neuropeptides, and opioid peptides.

Why This Research Matters

GH-deficient adults report improved mood, energy, and cognition on GH replacement. This study provides the first direct evidence that GH treatment changes brain chemistry, offering a biological explanation for these improvements.

The Bigger Picture

GH-deficient patients report improved mood, energy, and cognition on replacement therapy. This study provides a biological explanation: GH treatment actually changes the brain's chemical environment.

What This Study Doesn't Tell Us

Small study (10 per group). Only 1 month of treatment. CSF sampling is invasive and may have affected some measurements. Long-term brain chemistry effects unknown.

Questions This Raises

  • ?Which specific opioid peptide changes correlate with mood improvement?
  • ?Do the brain chemistry changes persist long-term?

Trust & Context

Key Stat:
Placebo-controlled proof Double-blind trial showing GH replacement directly changes brain opioid peptides, neurotransmitters, and growth factors
Evidence Grade:
Strong — double-blind, placebo-controlled RCT with direct CSF measurement. Gold-standard design despite small size.
Study Age:
Published in 1995 (31 years ago). GH replacement's neurological benefits are now well-recognized.
Original Title:
Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters.
Published In:
Neuroendocrinology, 61(1), 57-66 (1995)
Database ID:
RPEP-00324

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Does growth hormone affect the brain?

Yes — this study directly proved it. GH replacement increased brain GH and IGF-1 levels and changed neurotransmitter and opioid peptide concentrations in the cerebrospinal fluid.

Why do GH-deficient patients feel better on replacement?

This study suggests it's because GH treatment changes brain chemistry — altering monoamine neurotransmitters (affecting mood), neuropeptides (affecting stress response), and opioid peptides (affecting pain and well-being).

Read More on RethinkPeptides

Cite This Study

RPEP-00324·https://rethinkpeptides.com/research/RPEP-00324

APA

Johansson, J O; Larson, G; Andersson, M; Elmgren, A; Hynsjö, L; Lindahl, A; Lundberg, P A; Isaksson, O G; Lindstedt, S; Bengtsson, B A. (1995). Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters.. Neuroendocrinology, 61(1), 57-66.

MLA

Johansson, J O, et al. "Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters.." Neuroendocrinology, 1995.

RethinkPeptides

RethinkPeptides Research Database. "Treatment of growth hormone-deficient adults with recombinan..." RPEP-00324. Retrieved from https://rethinkpeptides.com/research/johansson-1995-treatment-of-growth-hormonedeficient

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.